API | potassium canrenoate

potassium canrenoate Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Potassium canrenoate or canrenoate potassium (USAN), also known as aldadiene kalium, the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group. Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body. ^Wikipedia

Chemistry

SMILES: C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@]4(O)CCC(=O)O
InChIKey: PBKZPPIHUVSDNM-WNHSNXHDSA-N
Mol. Mass: 358.48
ALogP: 3.89 Partition coefficient
ChEMBL Molecules:

canrenoate

canrenoate potassium

More Chemistry

Pharmacology

Mechanism of Action:
- Mineralocorticoid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Brain Diseases (Phase 2)

COVID-19 (Phase 4)

ST Elevation Myocardial Infarction (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue